Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Inclusion Criteria: * histologically confirmed HNSCC * adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal sinus, other head and neck site (except nasopharynx) * at least one measurable lesion * no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer than 6 months ago is permitted) * 18 years or older * ECOG 0 or 1 * adequate laboratory result * written, informed consent Exclusion Criteria: * pregnant or lactating women (negative pregnancy test within 7 days is required for women with potential of child-bearing) * experimental drug clinical trial within 30 days * other malignancy (exemption: treated basal cell carcinoma of skin, CIS, cured cancer with disease-free interval with more than 5 years) * patient with organ transplantation * grade 2 or more peripheral neuropathy * grade 2 or more hearing loss * severe, medical condition